Referencer – Kapitel 5

[524] 10 Cannabis-Based Drugs Produced By Big Pharma.

[525] Dagfinn Haarr, Sofie Haughom: Marihuana er effektiv medisin.—Dagfinn-Haarr_-Sofie-Haughom-8378238.html

[526] Cannabis får kræftceller til at begå selvmord.

[527] What Are The Medical Benefits of Marijuana?

What Exactly Is Unconstitutional About Plans To Limit THC?

What is Sativex (Nabiximols).

John M. McPartland, Ethan B. Russo: Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?

[528] Howard P, Twycross R, Shuster J, et al.: Cannabinoids. J Pain Symptom Manage 46 (1): 142-9, 2013. [PUBMED Abstract]

[529] Ordination af medicinsk cannabis.

[530] Derick T WadeChristine CollinColin Stott et al.: Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Multiple Sclerosis Journal Vol 16, Issue 6, 2010.

[531] Collin C1Davies PMutiboko IK. Et al.: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007 Mar;14(3):290-6.

[532] Portenoy RK1Ganae-Motan EDAllende S. et al.: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012 May;13(5):438-49. doi: 10.1016/j.jpain.2012.01.003. Epub 2012 Apr 5.

[533] 6 Takeaways From Dr. Ethan Russo’s ‘Cannabis: An Unconventional Solution to the Opioid Crisis’.

What is Sativex (Nabiximols).

[534] Turo J.Nurmikko, Mick G.Serpell, BarbaraHoggart et al.: Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. PAIN® Volume 133, Issues 1–3, 15 December 2007, Pages 210-220.

[535] Ethan B. RussoGeoffrey W. GuyPhilip J. Robson: Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine. Chemistry & Diversity Volume4, Issue8 August 2007 Pages 1729-1743.

[536] Blake DR1Robson PHo M. et al.: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50-2. Epub 2005 Nov 9.

[537] Kavia RB1De Ridder DConstantinescu CS. Et al.: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010 Nov;16(11):1349-59. doi: 10.1177/1352458510378020. Epub 2010 Sep 9.

[538] Berman JS1Symonds CBirch R.: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004 Dec;112(3):299-306.

[539] Jürgen KoehlerWolfgang FenebergMartin Meier: Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Journal  International Journal of Neuroscience Volume 124, 2014 – Issue 9

[540] Marijuana and Anxiety: A Guide.

[541] Why Does Marijuana Make You Paranoid?

[542] Sativex Oromucosal Spray.

[543] GW’s Epidiolex® Clinical Program.


GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome.

[545] Marijuana and muscle spasms.

How to Use Cannabis Tincture.

Medical Marijuana and Epilepsy.

[546] FDA and Marijuana: Questions and Answers.

Three Different Cannabinoid-Based Medicines Approved by the FDA

[547] What is THC (Tetrahydrocannabinol)?

[548] Tetrahydrocannabinol (THC).

[549] Marinol VS THC: What’s The Difference?

How Is Synthetic Weed Legal When It Kills?

What is Marinol (Dronabinol).

[550] Marinol.

Medical MariJuana: Furthering an Objective Debate. Canadian Journal Addiction. Volume 4 Number 3.

[551] Tramèr MR1Carroll DCampbell FA. Et al.: Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001 Jul 7;323(7303):16-21.

[552] Gorter R, Seefried M, Volberding P: Dronabinol effects on weight in patients with HIV infection. AIDS 6 (1): 127, 1992.

Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10 (2): 89-97, 1995.

What is Marinol (Dronabinol)?

Drugs@FDA: FDA Approved Drug Products.

Medical Marijuana vs. Marinol.

What Are The Medical Benefits of Marijuana?

Sallan SE, Zinberg NE, Frei E 3rd: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293 (16): 795-7, 1975. [PUBMED Abstract]

[553] Jeffrey E.Beal, Richard Olson, Linda Laubenstein et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management Volume 10, Issue 2, February 1995, Pages 89-97.

[554] Narang S1Gibson DWasan ADRoss EL et al.: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008 Mar;9(3):254-64. Epub 2007 Dec 21.

Medical Marijuana and Chronic Pain.

[555] Medical Marijuana and Fibromyalgia.

Schley M1Legler ASkopp G. et al.: Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin. 2006 Jul;22(7):1269-76.

[556] Medical Marijuana and Multiple Sclerosis (MS).

Svendsen KB1Jensen TSBach FW.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004 Jul 31;329(7460):253. Epub 2004 Jul 16.

[557] Carter GT1Abood MEAggarwal SKWeiss MD: Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care. 2010 Aug;27(5):347-56. doi: 10.1177/1049909110369531. Epub 2010 May 3.

Medical Marijuana and Amyotrophic Lateral Sclerosis (ALS).

[558] Prasad B1Radulovacki MGCarley DW: Proof of concept trial of dronabinol in obstructive sleep apnea. Front Psychiatry. 2013 Jan 22;4:1. doi: 10.3389/fpsyt.2013.00001. eCollection 2013.

Medical Marijuana and Sleep Apnea.

[559] Volicer L1Stelly MMorris JMcLaughlin J. et al.: Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997 Sep;12(9):913-9.

Medical Marijuana and Dementia.

[560] Christine A.,Rabinaka Mike, Angstadta Chandra, S.Sripada et al.: Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology Volume 64, January 2013, Pages 396-402.

Synthetic THC May Help in the Treatment of Phobias.

[561] Ordination af medicinsk cannabis.

[562] Medicinsk cannabis og cannabisbaseret medicin

[563] Drugs@FDA: FDA Approved Drug Products.

[564] Is a maker of deadly painkillers bankrolling the opposition of Arizona marijuana legalization?

[565] The non-weed biz world is zeroing in on legalization.

[566] Billionaire John Kapoor of Insys Therapeutics Arrested in Phoenix on Opioid Charges.

Opioid maker settles lawsuit over fentanyl spray.

Attorney General Brings Enforcement Action Against Opioid Pharmaceutical Company Insys Therapeutics For Its Unfair And Deceptive Marketing Practices Of Its Fentanyl Drug Subsys.

Dose of Justice.

[567] Insys founder Kapoor sued by New Jersey over opioid marketing campaign.

[568] Medicinsk cannabis og cannabisbaseret medicin

[569] Drugs@FDA: FDA Approved Drug Products.

[570] What is the entourage effect?


[571]Medicinsk cannabis og cannabisbaseret medicin.

[572] Berlach, D. M., Shir, Y., and Ware, M. A. (2006). Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 7: 25-29.

[573] Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D (2008). Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ,336:199. doi: 10.1136/bmj.39429.619653.80.

Toth, C., Mawani, S., Brady, S., Chan, C. and others. (2012). An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 153: 2073-2082.

[574] Ware, M. A., Fitzcharles, M. A., Joseph, L., and Shir, Y. (2010). The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth.Analg. 110: 604-610.

Skrabek, R. Q., Galimova, L., Ethans, K., and Perry, D. (2008). Nabilone for the treatment of pain in fibromyalgia. J.Pain. 9: 164-173.

[575] Fraser, G. A. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS.Neurosci.Ther. 15: 84-88.

[576] Pooyania, S., Ethans, K., Szturm, T., Casey, A. and others. (2010). A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch.Phys.Med.Rehabil. 91: 703-707.

[577] Marinol vs. Natural Plant.

[578] Cannabis Cannabinoids.

[579] Marijuana Terpenes Guide.

[580] Russo E1Guy GW: A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234-46. Epub 2005 Oct 4.

[581] Ethan B Russo: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug; 163(7): 1344–1364. doi:  10.1111/j.1476-5381.2011.01238.x.

[582] Physician’s Desk Reference: 43rd edition. Medical Economics Company. 1989: 1859-1860.

[583] Physician’s Desk Reference: 52nd edition. Medical Economics Company. 1998: 2353-2355.

[584] National Academy of Sciences, Institute of Medicine. 1999. Marijuana and medicine: Assessing the Science Base. p. 203. 1999. Washington, DC: The National Academies Press. .

[585] J. Morgan and L. Zimmer, Marijuana Myths, Marijuana Facts: A Review of the Scientific Evidence. The Lindesmith Center. 1997: 18-19.

[586] L. Lemberger et al. 1973. Comparative pharmacology of delta-9-THC and its metabolite 11-0H-Delta-9-THC. Journal of Clinical Investigation 54: 2411-2417.

M. Perez-Reyes et al. 1972. Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol. Science 177: 633-635.  

[587] L. Growing et al. 1998. Therapeutic use of cannabis: clarifying the debate. Drug and Alcohol Review. 17: 445-452.

[588] J. Morgan and L. Zimmer, Marijuana Myths, Marijuana Facts: A Review of the Scientific Evidence, 19.

[589] G. Carter et al. 2004. Medical marijuana: emerging applications for the management of neurologic disorders.  

A. Zuardi et al. 1982. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 76: 245-250.

G. Karinol et al. 1974. Cannabidiol interferes with the effects of delta-9-tetrahydrocannabinol in man. European Journal of Pharmacology 28: 172-177.

[590] D. Gieringer et al. 2004. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. Journal of Cannabis Therapeutics 4: 7-27.

[591] L. Growing et al. 1998. Therapeutic use of cannabis: clarifying the debate. Drug and Alcohol Review.

[592] National Academy of Sciences, Institute of Medicine. Of Marinol’s patient population, only about 10 percent use it to combat cancer-related nausea. 1999. Marijuana and Medicine: Assessing the Science Base. p. 204.

[593] E. Woolridge et al. 2005. Cannabis use in HIV for pain and other medical symptoms. Journal of Pain and Symptom Management 29: 358-67.

[594] J. McPartland and E. Russo. 2002. Cannabis and cannabis extracts: greater than the sum of their parts. Journal of Cannabis Therapeutics.

[595] Marijuana-like compound may aid array of debilitating conditions ranging from Parkinson’s Disease to pain. Society for Neuroscience. October 26, 2004. ScienceDaily. ScienceDaily, 27 October 2004.

[596] Pryce et al. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 126: 2191-2202.

[597] C. Raman et al. 2004. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 5: 33-39.

[598] I. Lastres-Becker et al. 2003. Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastraital injection of malonate. Neuroreport 14: 813-816.

[599] Ruth Gallily1, Zhannah Yekhtin1, Lumír Ondřej Hanuš: Overcoming the Bell‐Shaped

Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology & Pharmacy, 2015, 6, 75‐85. Published Online February 2015 in SciRes.

Synthetic vs. Whole Plant CBD.

[600] Conditions.

Taming THC.

[601] Tale of Two Cannabinoids.

[602] E. Williamson. 2001. Synergy and other interactions in phytomedicines. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 8: 401-409.

[603] A. Holdcroft. 2001. Cannabinoids: from plant to patient. Investigative Drugs Journal. 4: 773-775.

[604] J. McPartland and E. Russo. 2002. Cannabis and cannabis extracts: greater than the sum of their parts. Journal of Cannabis Therapeutics. p. 103.

[605] The Pharmaceutical Journal. “Cannabis herb may have advantages over THC in epilepsy.” July 19, 2003.

[606] D. Wade et al. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis 2004 Aug;10(4):434-41.

J. Zajicek et al. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis. Lancet. 362: 1517-26.

[607] Paul Armentano: Marinol Versus Natural Cannabis. Pros, Cons and Options for Patients. The National Organization for the Reform of Marijuana Laws.     

[608] R. Musty and R. Rossi. 2001. Effects of smoked cannabis and oral delta-9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. Journal of Cannabis Therapeutics. 1: 29-56.

[609] Board of Pharmacy, State of Tennessee. 1983. Annual Report: Evaluation of Marijuana and Tetrahydrocannabinol in Treatment of Nausea and/or Vomiting Associated with Cancer Therapy Unresponsive to Conventional Anti-Emetic Therapy: Efficacy and Toxicity. p. 5.

[610] Behavioral Health Services Division. 1983. The Lynn Pierson Therapeutic Research Program: A Report on Progress to Date. Health and Environment Department: New Mexico. p. 4.

[611] R. Schwartz and R. Beveridge. 1994. Marijuana as an antiemetic drug: how useful today. Opinions from clinical oncologists. Journal of Addictive Diseases 13: 53-65.

[612] R. Doblin and M. Kleiman. 1991. Marijuana as an anti-emetic medicine: a survey of oncologists’ attitudes and experiences. Journal of Clinical Oncology 19: 1275-1290.

[613] Research Advisory Panel. 1986. Seventeenth Annual Report of the Research Advisory Panel, p. 9-10.

[614] V. Vinciguerra et al. 1988. Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State Journal of Medicine 88: 525-527.

[615] E. Woolridge et al. 2005. Cannabis use in HIV for pain and other medical symptoms. Journal of Pain and Symptom Management.

[616] D. Prentiss et al. 2004. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. Journal of Acquired Immune Definiciency Syndromes 35: 38-45.

[617] R. Gorter et al. 2005. Medical use of cannabis in the Netherlands. Neurology 64: 917-919.

[618] Reuters News Wire. “Marijuana helps MS patients alleviate pain, spasms.” August 19, 2002.

Multiple Sclerosis.

[619] S. Page et al. 2003. Cannabis use as described by people with multiple sclerosis. Canadian Journal of Neurological Sciences 30: 201-205.

[620] A. Clark et al. 2004. Patterns of cannabis use among patients with multiple sclerosis. Neurology 62: 2098-2100.

[621] D. Gross et al. 2004. Marijuana use and epilepsy. Neurology 62: 2095-2097.

[622] News Wire. “Pot may ease Parkinson’s symptoms — Czech study.” November 13, 2002.

[623] Hazekamp A1Ware MAMuller-Vahl KR. et al.: The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210.